It has been more than a decade since
|
|
- Brook Richard
- 6 years ago
- Views:
Transcription
1 doi: /j x R EVIEW P APER Differentiating Pulmonary Arterial and Pulmonary Venous and the Implications for Therapy It has been more than a decade since the Second World Symposium on Pulmonary designated a new class of pulmonary hypertension (PH): PH associated with chronic left ventricular failure. 1 This class of PH became Group 2, or pulmonary venous hypertension (PVH), under the updated World Health Organization classification of the disease (Table I). 2,3 The acknowledgment of PH as a pathophysiologic sequelae of chronic left heart failure (HF) has led to some uncertainty about the appropriate diagnostic approach to certain patients with Group 2 hypertension. There exists a subset of Group 2 PH patients who develop a reactive hemodynamic profile that resultsinsevereph,similartothatseen in Group 1 PH or pulmonary arterial hypertension (PAH). While right heart catheterization (RHC) has become an essential tool in the diagnosis of Group 1PH,ithasbeenusedlessconsistently in the work-up of this subset of reactive Group 2 PH patients. Reliance on echocardiography alone for the clinical assessment of PVH can lead to misdiagnosis in these patients. PVH (also called postcapillary PH) arises as a consequence of either left HF, most commonly left ventricular () diastolic dysfunction, or valvular disease. 4 Elevated filling pressures in the setting of abnormal ventricular relaxation and compliance are transmitted back to the pulmonary venous circulation. Similarly, increased pulmonary blood flow resulting from mitral valve disease (functional or structural mitral regurgitation, mitral stenosis) can lead to elevations in pulmonary pressure. Traditionally, postcapillary PH has been defined as mean pulmonary artery pressure (mpap) 25 mm, pulmonary Pulmonary arterial and pulmonary venous hypertension develop from distinctly different etiologies. Pulmonary arterial hypertension (PAH), or Group 1 pulmonary hypertension (PH), is a precapillary PH that arises idiopathically or as the result of a divergent array of causes, including connective tissue disease. Pulmonary venous hypertension (PVH), or Group 2 PH, primarily manifests as a postcapillary PH in the setting of left heart failure or valvular disease. A subset of PVH patients, however, develop a reactive precapillary component of PH that mimics PAH.These patients can be misdiagnosed as having Group 1 PH by 2-dimensional echocardiography and are sometimes treated as such, which leads to exacerbation of heart failure. Therefore, 2-dimensional or Doppler echocardiography alone cannot be used to differentiate between these two classifications of PH. This highlights the need for right heart catheterization in the clinical assessment and diagnostic work-up of PH. The combination of imaging and invasive hemodynamic assessment by right heart catheterization provides the best diagnostic approach to ensure proper delineation of pulmonary arterial and pulmonary venous hypertension, and in turn leads to appropriate treatment. Congest Heart Fail. 2010;16: Ó 2010 Wiley Periodicals, Inc. Sina Dadfarmay, MD; 1 Robert Berkowitz, MD; 2 Bernard Kim, MD; 1 Rama Bindu Manchikalapudi, MD 1 From the Heart Failure and Pulmonary Program, Heart and Vascular Center, Hackensack University Medical Center, Hackensack, NJ, 1 and the Department of Medicine, 2 Hackensack University Medical Center, Hackensack, NJ Address for correspondence: Sina Dadfarmay, MD, Hackensack University Medical Center, Heart Failure and Pulmonary Program, 20 Prospect Avenue, Hackensack, NJ zerangi@hotmail.com Manuscript received November 23, 2009; revised April 10, 2010; accepted April 25, 2010 capillary wedge pressure (PCWP) 15 mm, and transpulmonic gradient (mpap)pcwp) <10 mm. However, in recent years, two different hemodynamic profiles in PVH have been recognized: passive and reactive postcapillary PH. In the former, there is passive retrograde transmission of elevated PCWP into the pulmonary venous system, causing a passive and mild increase in upstream PAP. 4 mpap increases only enough to overcome PCWP and maintain forward flow. As a result, the transpulmonic gradient (TPG) remains <10 mm. In contrast, in PAH, the TPG is 10 mm due to a low downstream PCWP (PCWP <15 mm ). In patients with passive PVH, PH can be reduced or attenuated by treatment of left HF and alleviation of elevated downstream wedge pressure or left atrial pressure. A subset of postcapillary PH patients, however, presents with a reactive hemodynamic profile and significantly elevated pulmonary pressures. These patients develop reactive changes in the pulmonary vasculature whereby increased pulmonary venous pressure triggers vascular smooth muscle and other vasoproliferative changes in the pulmonary arteries. This leads to obliter- differentiating pulmonary arterial and pulmonary venous hypertension november december
2 Table I. Revised World Health Organization Classification of Pulmonary Group 1: Pulmonary arterial hypertension Idiopathic (formerly primary pulmonary hypertension) Familial Collagen vascular disease Congenital systemic-to-pulmonary shunts Portal hypertension Human immunodeficiency virus Drugs and toxins (eg, cocaine) Glycogen storage disease Gaucher disease Hereditary hemorrhagic telangiectasia Hemoglobinopathies Myeloproliferative disorders Associated with significant venous or capillary involvement Pulmonary veno-occlusive disease Pulmonary capillary hemangiomatosis Group 2: Pulmonary venous hypertension Left ventricular systolic diastolic heart failure Left-sided valvular disease Group 3: Pulmonary hypertension associated with hypoxemia Chronic obstructive pulmonary disease Interstitial lung disease Obstructive sleep apnea Alveolar hypoventilation disorders Long-term exposure to high altitude Group 4: Pulmonary hypertension due to chronic thromboembolic disease Group 5: Miscellaneous Sarcoidosis Langerhans cell histiocytosis (histiocytosis X) Lymphangiomatosis Compression of pulmonary vessels (tumor, fibrosing mediastinitis) Adapted from Farber et al. 2 ative arteriopathy, a process thought to be mediated in part by endothelin. 5 The net result is reactive pulmonary vasoconstriction (both on the arterial and venous side), resulting in marked increases in PAP beyond that which is necessary to overcome elevated downstream PCWP. 4 Thus, these patients manifest with a precapillary component of PH marked by a TPG 10 mm as well as a significantly elevated pulmonary artery diastolic pressure (PADP > PCWP), hemodynamic changes that mimic PAH. Indeed, histological changes in the pulmonary vasculature of reactive PVH patients are indistinguishable from those of PAH patients. 1 PAP in this case does not normalize with treatment of underlying HF. Reactive PVH can occur in diastolic HF as well as in cases in which diastolic and systolic dysfunction coexist. It does not appear to develop in isolated systolic HF. 7 It was previously thought that the severity of PVH strongly correlated with the degree of systolic dysfunction. However, studies involving invasive measurements in patients with postcapillary PH showed that pulmonary pressures correlated more closely with diastolic indices, such as mitral valve deceleration time, than with systolic indices. 8,9 In fact, there was a poor correlation between PH and systolic indices in these patients. 8,9 Moreover, patients with the greatest degree of diastolic dysfunction had the highest PAP. 5 Thus, PVH is strongly associated with diastolic dysfunction, and, indeed, degree of diastolic dysfunction acts as an independent predictor of the severity of PH in HF. Patients with high-grade diastolic dysfunction who manifest with severe postcapillary PH may ultimately go on to develop a severe precapillary component of PH, which, in turn, can lead to right ventricular (RV) failure. In contrast, patients with isolated systolic HF develop a passive component of PH resulting from retrograde transmission of elevated filling pressure; however, they do not develop a reactive precapillary component. As such, they do not develop RV failure. PH in these patients is mitigated with diuretic therapy. In all PH patients, echocardiography is an essential tool in the initial clinical evaluation. PVH is typically diagnosed during the work-up of congestive HF and is most consistently seen in patients with diastolic dysfunction. 7 In the subset of patients with reactive PVH, the end result is similar to PAH. The right ventricle initially hypertrophies in response to the higher afterload brought on by increased PAP. Over time, this ultimately leads to dilatation and RV failure as the right ventricle is unable to maintain that level of systolic stress. 5 The echocardiographic findings in reactive PVH are nearly identical to those of PAH. There is marked RV and right atrial (RA) enlargement, flattening and leftward displacement of the interventricular septum, and, consequently, compression of the left ventricle. Classically, this results in a D-shaped left ventricle, as seen in the parasternal short-axis view. This process of ventricular interdependence is most prominent at endsystole. Therefore, there is a convergence of echocardiographic findings in Group 1 and reactive Group 2 PH whereby the same structural changes have evolved in response to different, but ultimately converging, pathophysiologies. We present two different cases of PH that exemplify the process of structural convergence as seen in this setting. Both patients were admitted to our HF service and initially diagnosed by echocardiography and subsequently by RHC. The first case is that of a 21-year-old woman (J.S.) with a history of atrial septal defect (ASD) who developed PAH (Group 1 PH) as a result of left-to-right intracardiac shunt and increased pulmonary flow. Over time and with the development of increasing pressures in the pulmonary circulation, her shunt became bidirectional and she developed Eisenmenger syndrome. Figure 1 illustrates the apical four-chamber view on echocardiogram demonstrating extensive RA and RV enlargement as a consequence of severe pressure overload on the right heart. The interventricular septum is flattened and displaced leftward, causing encroachment and compression of the left ventricle. Pulmonary artery systolic pressure (PASP) in this patient was estimated by echocardiogram to be 120 mm. Figure 2 shows the classic D-shaped left ventricle during systole in the same patient, again the result of severe pressure and volume overload on the right ventricle. The second case is that of a 70-yearold man (D.P.) with diastolic congestive HF who similarly developed right HF from severe PH. In this patient, diastolic dysfunction initially led to PVH by the mechanisms described earlier. Like other Group 2 PH patients with a reactive hemodynamic profile, our patient went on to develop a precapillary component of PH as a consequence of remodeling and vasoconstriction of the pulmonary arterial bed. As a result, he developed the hallmarks of acute RV failure, including peripheral edema, hepatomegaly, and ascites. As can be 288 differentiating pulmonary arterial and pulmonary venous hypertension november december 2010
3 RV RA Figure 1. Apical four-chamber view on echocardiogram in a patient with Group 1 pulmonary hypertension. The right atrium (RA) and right ventricle (RV) are severely dilated and there is flattening and reversal of septal curvature. The left ventricle () is small and compressed. indicates interventricular septum; LA, left atrium. RV Figure 2. Parasternal short-axis view of the interventricular septum () and left ventricle () showing a D-shaped morphology resulting from flattening and leftward displacement of the septum. RV indicates right ventricle. seen (Figure 3 and Figure 4), the echocardiographic findings in this patient closely mirror those of our PAH patient (J.S.), with severe enlargement of the right-sided chambers, flattening and leftward displacement of the septum, and the resultant formation of a D-shaped left ventricle. Following initial diagnostic evaluation by echocardiogram, each patientunderwentrhc forinvasive hemodynamic assessment. The results are shownintableii.thekeydifference between the Group 1 and Group 2 PH patients was the filling pressure, reflected by the PCWP. The wedge pressure was significantly elevated in the patient with left HF, as expected, but normal in the patient with PAH. Mean LA PAPs in both patients were severely increased; PASP obtained by RHC mirrored values obtained by echocardiography. Similar to the Group 1 patient, the Group 2 patient manifested with a transpulmonic gradient >10 mm, indicating a precapillary, reactive component to the PH. Thus, although there was a structural convergence in the evolution of precapillary PH in these two patients, as demonstrated by two-dimensional echocardiogram, only by catheterization were the two differing etiologies discernable. Interestingly, in both patients, cardiac output was seemingly preserved. Typically in cases of severe precapillary PH in which the right ventricle is dilated and hypokinetic, there is a diminution of cardiac output. As a result, these patients tend to be hypotensive. In the Group 1 patient (J.S.), cardiac output was maintained by bidirectional shunting through the ASD. In the Group 2 patient (D.P.), the high cardiac output was likely the result of shunting secondary to hepatic insufficiency along with global reduction in systemic vascular resistance in the setting of liver failure and congestive hepatopathy. A useful adjunct to traditional two-dimensional echocardiography for the assessment of LA and filling pressure as well as diastolic dysfunction in patients with postcapillary PH is Doppler echocardiography. Doppler parameters predicting increased PCWP include shortened deceleration time of early diastolic mitral inflow velocity (E), the ratio between mitral inflow velocity and mitral annular velocity in early diastole (E E 0 ), and the difference between pulmonary vein atrial flow reversal velocity (PVa) and mitral inflow velocity during atrial systole (A). E A ratios are used to quantify grade of diastolic dysfunction. While these variables may suggest elevated wedge pressure and associated diastolic dysfunction, a definitive measurement of PCWP and corresponding end-diastolic pressure is best determined by RHC, as demonstrated above. Hence, Doppler examination can be a useful noninvasive tool in the work-up of PH, but more invasive hemodynamic evaluation is required to ultimately differentiate precapillary from postcapillary PH. Apart from the difference in PCWP, the other important feature distinguishinggroup1andgroup2phpatientsis grade of diastolic dysfunction. Group 1 patients with RV failure develop low-grade diastolic dysfunction as a result of ventricular interdependence, as described above. However, the grade of diastolic dysfunction in these patients almost never exceeds grade 1, and this does not change with therapy. In contrast, Group 2 PH patients with RV failure (ie, patients with a reactive precapillary PH component) nearly always manifest with grade 2 to 3 diastolic dysfunction. Indeed, what appears to predict the development of a precapillary differentiating pulmonary arterial and pulmonary venous hypertension november december
4 Figure 3. Apical four-chamber view on echocardiogram in a patient with Group 2 pulmonary hypertension. Note severe enlargement of the right atrium(ra), right ventricle (RV), and reciprocal compression of the left ventricle () by a displaced septum. indicates interventricular septum; LA, left atrium. Table II. Right Heart Catheterization Data HEMODYNAMIC VARIABLES RV Figure 4. Parasternal short-axis view exhibiting the formation of a D-shaped left ventricle () in a patient with Group 2 pulmonary hypertension. RV indicates right ventricle;, interventricular septum. PATIENT 1 (PAH, GROUP 1 PH) PATIENT 2 (PVH, GROUP 2 PH) RAP, mm RVP, mm PAP, mean, mm (76) (63) PCWP, mm CO, L min a CI, L min m Abbreviations: CI, cardiac index; PAH, pulmonary arterial hypertension; PAP, pulmonary artery pressure; PCWP, pulmonary capillary wedge pressure; PH, pulmonary hypertension; PVH, pulmonary venous hypertension; RAP, right atrial pressure; RVP, right ventricular pressure. a Cardiac output (CO) was measured by Fick. component in Group 2 PH is the severity of diastolic dysfunction. These cases illustrate the importance of RHC in the clinical assessment and diagnosis of PH. Doppler echocardiography is an appropriate initial screening tool in patients with suspected PH based on history or physical examination findings. When echocardiographic findings reveal PH based on elevated RV systolic pressure and there is evidence of RV dilatation and or RV systolic dysfunction, patients must be referred for RHC as the next step. As demonstrated here by structural convergence, a diagnosis of PAH vs reactivepvhcannotbemadebyechocardiography alone. Sole reliance on imaging for a diagnosis of PAH in patients found to have severely elevated PAP and echocardiographic evidence of right HF can lead to misdiagnosis of a Group 2 PH patient as Group 1 PH. This, in turn, has dangerous implications on treatment of these patients, as studies have shown that pulmonary vasodilator therapy worsens HF in Group 2 PH patients. Vasodilators increase venous return to the left heart, which, in the setting of already elevated filling pressures, can precipitate pulmonary edema. In fact, epoprostenol has been associated with increased mortality in patients with systolic HF. 4 No treatment has been shown to be effective for reactive PVH in patients with left HF. This holds true even after normalization of wedge pressure in these patients following diuretic therapy. RHC remains the gold standard for the diagnosis of PH and its divergent causes. Table III shows the classic hemodynamic profile for precapillary and postcapillary PH obtained by RHC. Comprehensive clinical assessment in every patient should never rely on imaging alone but rather the integration of echo-doppler with invasive hemodynamic data. Understanding the physiology and hemodynamic profile of the RV,, and pulmonary circulation is critical for differentiating between precapillary and postcapillary PH and, in turn, ensures the appropriate treatment (Figure 5). Further testing is necessary to discern other non Group 1 causes of precapillary PH that may not be amenable to pulmonary vasodilator therapy. 290 differentiating pulmonary arterial and pulmonary venous hypertension november december 2010
5 Table III. Hemodynamic and Echo-Doppler Differences Between Group 1 and Group 2 Pulmonary CLASSIFICATION PCWP MPAP TRANSPULMONIC GRADIENT a PA EDP-PCWP GRADE OF DIASTOLIC DYSFUNCTION Group 1 PH (PAH) < None or 1 Group 2 PH (PVH) Passive <10 <10 1 Reactive All pressures are given in mm and derived by right heart catheterization. Diastolic grade was obtained from Doppler echocardiographic evaluation of transmitral velocities as well as tissue Doppler echocardiography. Abbreviations: mpap, mean pulmonary artery pressure; PA EDP, pulmonary artery end-diastolic pressure; PAH, pulmonary arterial hypertension; PCWP, pulmonary capillary wedge pressure; PH, pulmonary hypertension; PVH, pulmonary venous hypertension. a Transpulmonic gradient = mpap)pcwp. PA Precapillary Pulmonary Postcapillary Pulmonary LA Group 1 PH (PAH) o PCWP < 15 mm o PAP-PCWP > 10 mm Diastolic heart failure with reactive PH o PCWP 15 mm o PAP-PCWP > 10 mm Systolic heart failure Diastolic heart failure with passive PH o PCWP 15 mm o PAP-PCWP< 10 mm Valvular heart disease Figure 5. Anatomic overview of precapillary and postcapillary pulmonary hypertension (PH). PA indicates pulmonary artery; RA, right atrium; RV, right ventricle; PAH, pulmonary arterial hypertension; PCWP, pulmonary capillary wedge pressure; PAP, pulmonary artery pressure; LA, left atrium;, left ventricle. REFERENCES 1 Bonderman D, Martischnig AM, Moertl D, Lang IM. Pulmonary hypertension in chronic heart failure. Int J Clin Pract. 2009;63: Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004;351: Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43(12 suppl S): 5S 12S. 4 Rich S, Rabinovitch M. Diagnosis and treatment of secondary (non-category 1) pulmonary hypertension. Circulation. 2008;118: Zakir RM, Al-Dehneh A, Maher J, et al. Right ventricular failure in patients with preserved ejection fraction and diastolic dysfunction: an underrecognized clinical entity. Congest Heart Fail. 2007;13(3): Hemnes AR, Forfia PR, Champion HC. Assessment of pulmonary vasculature and right heart by invasive haemodynamics and echocardiography. Int J Clin Practice. 2009;63: Moraes DL, Colucci WS, Givertz MM. Secondary pulmonary hypertension in chronic heart failure. Circulation. 2000;102: Enriquez-Sarano M, Rossi A, Seward JB, et al. Determinants of pulmonary hypertension in left ventricular dysfunction. J Am Coll Cardiol. 1997;29(1): Capomolla S, Febo O, Guazzotti G, et al. Invasive and non-invasive determinants of pulmonary hypertension in patients with chronic heart failure. J Heart Lung Transplant. 2000;19: differentiating pulmonary arterial and pulmonary venous hypertension november december
Right Ventricular Failure and Pulmonary Hypertension 2011
Right Ventricular Failure and Pulmonary Hypertension 2011 George G. Sokos, DO FACC Assistant Professor of Medicine, Temple University Director, Advanced Heart Failure and Cardiac Transplant Fellowship
More informationPULMONARY HYPERTENSION
PULMONARY HYPERTENSION REVIEW & UPDATE Olga M. Fortenko, M.D. Pulmonary & Critical Care Medicine Pulmonary Vascular Diseases Sequoia Hospital 650-216-9000 Olga.Fortenko@dignityhealth.org Disclosures None
More informationDisclosures. Objectives 6/16/2016. A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension
A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension Susan P. D Anna MSN, APN-BC, CHFN June 24, 2016 Disclosures Objectives Differentiate structure and function of RV and LV
More informationPulmonary Hypertension: Another Use for Viagra
Pulmonary Hypertension: Another Use for Viagra Kathleen Tong, MD Director, Heart Failure Program Assistant Clinical Professor University of California, Davis Disclosures I have no financial conflicts A
More informationDisclosures. Objectives. RV vs LV. Structure and Function 9/25/2016. A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension
Disclosures A Look at the Other Side: Focus on the Right Ventricle and Pulmonary Hypertension No financial relationships Susan P. D Anna MSN, APN BC, CHFN September 29, 2016 Objectives RV vs LV Differentiate
More informationPulmonary hypertension
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2012 Pulmonary hypertension Glaus, T M Posted at the Zurich Open Repository
More informationEvaluation of Left Ventricular Diastolic Dysfunction by Doppler and 2D Speckle-tracking Imaging in Patients with Primary Pulmonary Hypertension
ESC Congress 2011.No 85975 Evaluation of Left Ventricular Diastolic Dysfunction by Doppler and 2D Speckle-tracking Imaging in Patients with Primary Pulmonary Hypertension Second Department of Internal
More informationDr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college
Dr. Md. Rajibul Alam Prof. of Medicine Dinajpur Medical college PULMONARY HYPERTENSION Difficult to diagnose early Because Not detected during routine physical examination and Even in advanced cases symptoms
More informationPulmonary Hypertension in 2012
Pulmonary Hypertension in 2012 Evan Brittain, MD December 7, 2012 Kingston, Jamaica VanderbiltHeart.com Disclosures None VanderbiltHeart.com Outline Definition and Classification of PH Hemodynamics of
More informationCor pulmonale. Dr hamid reza javadi
1 Cor pulmonale Dr hamid reza javadi 2 Definition Cor pulmonale ;pulmonary heart disease; is defined as dilation and hypertrophy of the right ventricle (RV) in response to diseases of the pulmonary vasculature
More informationRight Heart Catheterization. Franz R. Eberli MD Chief of Cardiology Stadtspital Triemli, Zurich
Right Heart Catheterization Franz R. Eberli MD Chief of Cardiology Stadtspital Triemli, Zurich Right Heart Catheterization Pressure measurements Oxygen saturation measurements Cardiac output, Vascular
More informationPulmonary Hypertension: Clinical Features & Recent Advances
Pulmonary Hypertension: Clinical Features & Recent Advances Lisa J. Rose-Jones, MD Assistant Professor of Medicine, Division of Cardiology Advanced Heart Failure/Cardiac Transplantation & Pulmonary Hypertension
More informationPulmonary Hypertension: Definition and Unmet Needs
Heart Failure Center Hadassah University Hospital Pulmonary Hypertension: Definition and Unmet Needs Israel Gotsman The Heart Failure Center Hadassah University Hospital I DO NOT have a financial interest/
More informationAssessing the Impact on the Right Ventricle
Advances in Tricuspid Regurgitation Congress of the European Society of Cardiology (ESC) Munich, August 25-29, 2012 Assessing the Impact on the Right Ventricle Stephan Rosenkranz, MD Clinic III for Internal
More informationPVDOMICS. Study Introduction. Kristin Highland, MD Gerald Beck, PhD. NHLBI Pulmonary Vascular Disease Phenomics Program
PVDOMICS Study Introduction Kristin Highland, MD Gerald Beck, PhD NHLBI Pulmonary Vascular Disease Phenomics Program Funded by the National Heart, Lung, and Blood Institute of the National Institutes of
More informationLV geometric and functional changes in VHD: How to assess? Mi-Seung Shin M.D., Ph.D. Gachon University Gil Hospital
LV geometric and functional changes in VHD: How to assess? Mi-Seung Shin M.D., Ph.D. Gachon University Gil Hospital LV inflow across MV LV LV outflow across AV LV LV geometric changes Pressure overload
More information2/4/2011. Nathan Kerner, M.D.
Nathan Kerner, M.D. Definition Elevated pressures - cut off usually >40 mmhg pulmonary artery systolic pressure (PASP) Usually associated with elevated pulmonary vascular resistance (PVR) measured in dynessec/cm
More informationΕιδικές θεραπείες σε µη-αρτηριακή πνευµονική υπέρταση, πότε; - Στέλλα Μπρίλη Α Πανεπιστηµιακή Καρδιολογική Κλινική Ιπποκράτειο Νοσοκοµείο Αθηνών
Ειδικές θεραπείες σε µη-αρτηριακή πνευµονική υπέρταση, πότε; - Στέλλα Μπρίλη Α Πανεπιστηµιακή Καρδιολογική Κλινική Ιπποκράτειο Νοσοκοµείο Αθηνών . Updated Clinical Classification of Pulmonary Hypertension
More informationPulmonary Hypertension Perioperative Management
Pulmonary Hypertension Perioperative Management Bruce J Leone, MD Professor of Anesthesiology Chief, Neuroanesthesiology Vice Chair for Academic Affairs Mayo Clinic Jacksonville, Florida Introduction Definition
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
European Medicines Agency London, 18 December 2008 Doc. Ref. EMEA/CHMP/EWP/356954/2008 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT CHMP GUIDELINE ON THE CLINICAL INVESTIGATIONS OF MEDICINAL
More informationPVDOMICS. Study Introduction. Kristin Highland, MD Gerald Beck, PhD. NHLBI Pulmonary Vascular Disease Phenomics Program
PVDOMICS Study Introduction Kristin Highland, MD Gerald Beck, PhD NHLBI Pulmonary Vascular Disease Phenomics Program Funded by the National Heart, Lung, and Blood Institute of the National Institutes of
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.15 Subject: Flolan Veletri Page: 1 of 5 Last Review Date: September 15, 2017 Flolan Veletri Description
More informationValutazione del neonato con sospetta ipertensione polmonare
Valutazione del neonato con sospetta ipertensione polmonare Cardiologia Pediatrica Seconda Università degli Studi di Napoli A.O. R.N. dei Colli-Monaldi Napoli Hypoxiemic infant Full or near-term neonate
More informationThe Hemodynamics of PH Interpreting the numbers
The Hemodynamics of PH Interpreting the numbers Todd M Bull MD Associate Professor of Medicine Division of Pulmonary Sciences and Critical Care Medicine Pulmonary Hypertension Center University of Colorado
More informationTopics to be Covered. Cardiac Measurements. Distribution of Blood Volume. Distribution of Pulmonary Ventilation & Blood Flow
Topics to be Covered MODULE F HEMODYNAMIC MONITORING Cardiac Output Determinants of Stroke Volume Hemodynamic Measurements Pulmonary Artery Catheterization Control of Blood Pressure Heart Failure Cardiac
More informationMultimodality imaging for PAH: Is CT better than MRI?
UNIVERSITÀ DEGLI STUDI DI TORINO Facoltà di Medicina e Chirurgia Dipartimento di Scienze Chirurgiche Istituto di Radiologia Azienda Ospedaliera Universitaria Città della Salute e della scienza di Torino
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.21 Subject: Orenitram Page: 1 of 6 Last Review Date: June 24, 2016 Orenitram Description Orenitram
More informationPathophysiology: Left To Right Shunts
Pathophysiology: Left To Right Shunts Daphne T. Hsu, MD dh17@columbia.edu Learning Objectives Learn the relationships between pressure, blood flow, and resistance Review the transition from fetal to mature
More informationPulmonary Hypertension. Echocardiography: Pearls & Pitfalls
Pulmonary Hypertension Echocardiography: Pearls & Pitfalls Αθανάσιος Γ. Κουτσάκης Ειδικευόμενος Καρδιολογίας Α Καρδιολογική Κλινική ΑΠΘ Σεμινάρια Ομάδων Εργασίας Ελληνικής Καρδιολογικής Εταιρείας Ιωάννινα,
More informationPulmonary Hypertension: Echocardiographic Evaluation of Pulmonary Hypertension and Right Ventricular Function. Irmina Gradus-Pizlo, MD
Pulmonary Hypertension: Echocardiographic Evaluation of Pulmonary Hypertension and Right Ventricular Function Irmina Gradus-Pizlo, MD Disclosures: Nothing to disclose Overview Is pulmonary hypertension
More informationADCIRCA (tadalafil) The World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Pulmonary arterial hypertension is a rare disorder of the pulmonary arteries in which the pulmonary arterial pressure rises above normal levels in the absence
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.13 Section: Prescription Drugs Effective Date: July 1 2016 Subject: Tyvaso Page: 1 of 4 Last Review
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.16 Subject: Letairis Page: 1 of 6 Last Review Date: June 24, 2016 Letairis Description Letairis (ambrisentan)
More informationΚαθετηριασμός δεξιάς κοιλίας. Σ. Χατζημιλτιάδης Καθηγητής Καρδιολογίας ΑΠΘ
Καθετηριασμός δεξιάς κοιλίας Σ. Χατζημιλτιάδης Καθηγητής Καρδιολογίας ΑΠΘ The increasing interest in pulmonary arterial hypertension (PAH), the increasing interest in implantation of LVADs, and the evolution
More informationREVATIO (sildenafil)
RATIONALE FOR INCLUSION IN PA PROGRAM Background Pulmonary arterial hypertension is a rare disorder of the pulmonary arteries in which the pulmonary arterial pressure rises above normal levels in the absence
More informationPDE5 INHIBITOR POWDERS Sildenafil powder, Tadalafil powder
RATIONALE FOR INCLUSION IN PA PROGRAM Background Sildenafil and Tadalafil are marketed as Revatio and Adcirca for pulmonary arterial hypertension. This is a rare disorder of the pulmonary arteries in which
More information2nd ECHO ASE-ASEAN: Bangkok 22nd October DR. TAN JU LE Pulmonary Hypertension Services National Heart Centre SINGAPORE
2nd ECHO ASE-ASEAN: Bangkok 22nd October 2016 DR. TAN JU LE Pulmonary Hypertension Services National Heart Centre SINGAPORE Definition of Pulmonary Hypertension and Cor Pulmonale Epidemiology and Pathophysiology
More informationSildenafil Citrate Powder. Sildenafil citrate powder. Description. Section: Prescription Drugs Effective Date: January 1, 2016
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.06.15 Subject: Sildenafil Citrate Powder Page: 1 of 6 Last Review Date: December 3, 2015 Sildenafil Citrate
More informationDECLARATION OF CONFLICT OF INTEREST
DECLARATION OF CONFLICT OF INTEREST ESC Congress 2011 Pathophysiology of HFPEF Vascular Remodeling & Pulmonary Hypertension Carolyn S.P. Lam MBBS, MRCP, MS Case Presentation 81 yo woman with dyspnoea &
More informationClinical implication of exercise pulmonary hypertension: when should we measure it?
Clinical implication of exercise pulmonary hypertension: when should we measure it? Jang-Young, Kim Wonju College of Medicine, Yonsei Univ. Exercise pulmonary hypertension (EPH) Introduction of pulmonary
More informationNeonatal and Pediatric Pulmonary Vascular Disease
Neonatal and Pediatric Pulmonary Vascular Disease Emma Olson, MS, ARNP Pediatric Cardiology Nurse Practitioner Canadian Respiratory Conference April 14, 2018 Financial Interest Disclosure (over the past
More informationAdel Hasanin Ahmed 1
Adel Hasanin Ahmed 1 PERICARDIAL DISEASE The pericardial effusion ends anteriorly to the descending aorta and is best visualised in the PLAX. PSAX is actually very useful sometimes for looking at posterior
More informationPathophysiology: Left To Right Shunts
Pathophysiology: Left To Right Shunts Daphne T. Hsu, MD dh17@columbia.edu Learning Objectives Learn the relationships between pressure, blood flow, and resistance Review the transition from fetal to mature
More informationInstructions: This form is completed and entered for all participants. Database will skip over sections that do not apply.
Revision of 08/30/2017 Form #102 Page 1 of 6 PVDOMICS STUDY PVD Assessment - Form #102 Instructions: This form is completed and entered for all participants. Database will skip over sections that do not
More informationMITRAL STENOSIS. Joanne Cusack
MITRAL STENOSIS Joanne Cusack BSE Breakdown Recognition of rheumatic mitral stenosis Qualitative description of valve and sub-valve calcification and fibrosis Measurement of orifice area by planimetry
More informationAcute Vasodilator Testing in Pulmonary Hypertension: What, When, and How?
Acute Vasodilator Testing in Pulmonary Hypertension: What, When, and How? Teresa De Marco, MD University of California, San Francisco Disclosures: Grants/Research: United Therapeutics, Lung Biotechnology,
More informationBrief View of Calculation and Measurement of Cardiac Hemodynamics
Cronicon OPEN ACCESS EC CARDIOLOGY Review Article Brief View of Calculation and Measurement of Cardiac Hemodynamics Samah Alasrawi* Pediatric Cardiologist, Al Jalila Children Heart Center, Dubai, UAE *
More informationTricuspid and Pulmonic Valve Disease
Chapter 31 Tricuspid and Pulmonic Valve Disease David A. Tate Acquired disease of the right-sided cardiac valves is much less common than disease of the leftsided counterparts, possibly because of the
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.17 Subject: Remodulin Page: 1 of 5 Last Review Date: June 24, 2016 Remodulin Description Remodulin
More informationPulmonary Hypertension Due to Left Heart Disease
ACC Middle East Conference 2018 Pulmonary Hypertension Due to Left Heart Disease Ammar Chaudhary, MBChB, FRCPC Advanced Heart Failure & Transplantation King Faisal Specialist Hospital and Research Center
More informationEcho in Pulmonary HTN
Echo in Pulmonary HTN Steven A. Goldstein MD FACC FASE Professor of Medicine Georgetown University Medical Center MedStar Heart Institute Washington Hospital Center Monday, October 10, 2017 Pulmonary Artery
More informationAnjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program
Anjali Vaidya, MD, FACC, FASE, FACP Associate Director, Pulmonary Hypertension, Right Heart Failure, and Pulmonary Thromboendarterectomy Program Advanced Heart Failure & Cardiac Transplant Temple University
More informationUnexplained Pulmonary Hypertension in Elderly Patients* Brian P. Shapiro, MD; Michael D. McGoon, MD, FCCP; and Margaret M.
CHEST Unexplained Pulmonary Hypertension in Elderly Patients* Brian P. Shapiro, MD; Michael D. McGoon, MD, FCCP; and Margaret M. Redfield, MD Original Research PULMONARY HYPERTENSION Background: Idiopathic
More informationPERICARDIAL DIAESE. Kaijun Cui Associated professor Sichuan University
PERICARDIAL DIAESE Kaijun Cui Associated professor Sichuan University CLASSIFICATION acute pericarditis pericardial effusion cardiac tamponade constrictive pericarditis congenitally absent pericardium
More informationThe Doppler Examination. Katie Twomley, MD Wake Forest Baptist Health - Lexington
The Doppler Examination Katie Twomley, MD Wake Forest Baptist Health - Lexington OUTLINE Principles/Physics Use in valvular assessment Aortic stenosis (continuity equation) Aortic regurgitation (pressure
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.10 Subject: Uptravi Page: 1 of 6 Last Review Date: September 15, 2017 Uptravi Description Uptravi
More informationPulmonary Hypertension and Left Heart Disease: What s good for the goose is not necessary good for the gander
Pulmonary Hypertension and Left Heart Disease: What s good for the goose is not necessary good for the gander Jacqueline Fearon-Clarke, MA, ACNP-BC Heart Failure and Pulmonary Hypertension Nurse Practitioner
More informationAdult Echocardiography Examination Content Outline
Adult Echocardiography Examination Content Outline (Outline Summary) # Domain Subdomain Percentage 1 2 3 4 5 Anatomy and Physiology Pathology Clinical Care and Safety Measurement Techniques, Maneuvers,
More informationDr.Fayez EL Shaer Consultant cardiologist Assistant professor of cardiology KKUH
Pulmonary Hypertension in patients with Heart Failure with Preserved Ejection Fraction Dr.Fayez EL Shaer Consultant cardiologist Assistant professor of cardiology KKUH Recent evaluation of available data
More informationRecruitment and Consenting
1 Recruitment and Consenting MOP Chapter 4 NHLBI Pulmonary Vascular Disease Phenomics Program Funded by the National Heart, Lung, and Blood Institute of the National Institutes of Health with support from
More informationPaediatric PAH in the current era
Paediatric PAH in the current era Dunbar Ivy, MD The Children s Hospital Heart Institute University of Colorado School of Medicine Paediatric PAH in the current era & A Gap Analysis Dunbar Ivy, MD The
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Tracleer Page: 1 of 6 Last Review Date: September 15, 2017 Tracleer Description Tracleer (bosentan)
More informationObjectives. Diastology: What the Radiologist Needs to Know. LV Diastolic Function: Introduction. LV Diastolic Function: Introduction
Objectives Diastology: What the Radiologist Needs to Know. Jacobo Kirsch, MD Cardiopulmonary Imaging, Section Head Division of Radiology Cleveland Clinic Florida Weston, FL To review the physiology and
More informationPulmonary Heart Disease: Evaluation and Management
Pulmonary Heart Disease: Evaluation and Management Robert C. Bourge, MD Professor of Medicine, Radiology, and Surgery Drummond Chair of Cardiovascular Medicine Vice Chair of Clinical Affairs, Department
More informationThe right ventricle in chronic heart failure
The right ventricle in chronic heart failure ESC 2012 Christian Opitz, Berlin There are no conflicts of interest relevant to this presentation Percent of Population Prevalence of Heart Failure by Age and
More informationLeft atrial function. Aliakbar Arvandi MD
In the clinic Left atrial function Abstract The left atrium (LA) is a left posterior cardiac chamber which is located adjacent to the esophagus. It is separated from the right atrium by the inter-atrial
More informationACTIVITY DESCRIPTION Target Audience Learning Objectives
ACTIVITY DESCRIPTION Target Audience This continuing medical education activity is planned to meet the needs of primary care physicians who can contribute to early detection of disease and who are responsible
More informationHISTORY. Question: What category of heart disease is suggested by the fact that a murmur was heard at birth?
HISTORY 23-year-old man. CHIEF COMPLAINT: Decreasing exercise tolerance of several years duration. PRESENT ILLNESS: The patient is the product of an uncomplicated term pregnancy. A heart murmur was discovered
More informationHISTORY. Question: How do you interpret the patient s history? CHIEF COMPLAINT: Dyspnea of two days duration. PRESENT ILLNESS: 45-year-old man.
HISTORY 45-year-old man. CHIEF COMPLAINT: Dyspnea of two days duration. PRESENT ILLNESS: His dyspnea began suddenly and has been associated with orthopnea, but no chest pain. For two months he has felt
More informationThe World Health Organization (WHO) has classified pulmonary hypertension into five different groups: (2)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.40.23 Subject: Sildenafil Citrate Powder Page: 1 of 6 Last Review Date: September 15, 2017 Sildenafil
More information22nd Annual Heart Failure 2018 an Update on Therapy. Pulmonary Arterial Hypertension: Contemporary Approach to Treatment
22nd Annual Heart Failure 2018 an Update on Therapy Pulmonary Arterial Hypertension: Contemporary Approach to Treatment Ronald J. Oudiz, MD, FACP, FACC, FCCP Professor of Medicine The David Geffen School
More informationAppendix II: ECHOCARDIOGRAPHY ANALYSIS
Appendix II: ECHOCARDIOGRAPHY ANALYSIS Two-Dimensional (2D) imaging was performed using the Vivid 7 Advantage cardiovascular ultrasound system (GE Medical Systems, Milwaukee) with a frame rate of 400 frames
More informationEcho in Heart Failure
Echo in Heart Failure Karima Addetia, MD Heart Failure: Definition A clinical syndrome that results from impairment of ventricular filling or ejection of blood. Manifestations include dyspnea and fatigue,
More informationEffective Strategies and Clinical Updates in Pulmonary Arterial Hypertension
Effective Strategies and Clinical Updates in Pulmonary Arterial Hypertension Hap Farber Director, Pulmonary Hypertension Center Boston University School of Medicine Disclosures 1) Honoria: Actelion, Gilead,
More informationHeart Failure. Cardiac Anatomy. Functions of the Heart. Cardiac Cycle/Hemodynamics. Determinants of Cardiac Output. Cardiac Output
Cardiac Anatomy Heart Failure Professor Qing ZHANG Department of Cardiology, West China Hospital www.blaufuss.org Cardiac Cycle/Hemodynamics Functions of the Heart Essential functions of the heart to cover
More informationBasic Approach to the Echocardiographic Evaluation of Ventricular Diastolic Function
Basic Approach to the Echocardiographic Evaluation of Ventricular Diastolic Function J A F E R A L I, M D U N I V E R S I T Y H O S P I T A L S C A S E M E D I C A L C E N T E R S T A F F C A R D I O T
More informationHEMODYNAMIC ASSESSMENT
HEMODYNAMIC ASSESSMENT INTRODUCTION Conventionally hemodynamics were obtained by cardiac catheterization. It is possible to determine the same by echocardiography. Methods M-mode & 2D echo alone can provide
More informationSqueeze, Squeeze, Squeeze: The Importance of Right Ventricular Function and PH
Squeeze, Squeeze, Squeeze: The Importance of Right Ventricular Function and PH Javier Jimenez MD PhD FACC Director, Advanced Heart Failure and Pulmonary Hypertension Miami Cardiac & Vascular Institute
More informationHemodynamic Assessment. Assessment of Systolic Function Doppler Hemodynamics
Hemodynamic Assessment Matt M. Umland, RDCS, FASE Aurora Medical Group Milwaukee, WI Assessment of Systolic Function Doppler Hemodynamics Stroke Volume Cardiac Output Cardiac Index Tei Index/Index of myocardial
More information8/31/2016. Mitraclip in Matthew Johnson, MD
Mitraclip in 2016 Matthew Johnson, MD 1 Abnormal Valve Function Valve Stenosis Obstruction to valve flow during that phase of the cardiac cycle when the valve is normally open. Hemodynamic hallmark - pressure
More informationDisclosure. RV is not the innocent bystander 10/1/16. Assessment and Management of Pulmonary Heart Disease in the Female Patient
Assessment and Management of Pulmonary Heart Disease in the Female Patient Oct 1, 2016 Deborah Women s Heart Center Susan E Wiegers, MD, FASE, FACC Professor of Medicine Senior Associate Dean of Faculty
More informationUncommon Doppler Echocardiographic Findings of Severe Pulmonic Insufficiency
Uncommon Doppler Echocardiographic Findings of Severe Pulmonic Insufficiency Rahul R. Jhaveri, MD, Muhamed Saric, MD, PhD, FASE, and Itzhak Kronzon, MD, FASE, New York, New York Background: Two-dimensional
More informationPulmonary Hypertension: ICD-10 I27.0, I27.2
Dr Manish Barman, MD. Membership and Affiliations ESC, European association of cardiovascular prevention and rehabilitation. Acute Cardiovascular Care Association. ESC, Working Group on Hypertension &
More informationPathophysiology: Heart Failure
Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Medicine Outline Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology Heart Failure: Definitions
More informationTherapeutic Advances in Respiratory Disease. Original Research
573373TAR0010.1177/1753465815573373Therapeutic Advances in Respiratory DiseaseC Howard, K Rangajhavala research-article2015 Therapeutic Advances in Respiratory Disease Original Research Pulmonary artery
More informationCardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON
Cardiac Catheterization is Unnecessary in the Evaluation of Patients with Pulmonary Hypertension: CON Dunbar Ivy, MD The Children s s Hospital Heart Institute 1 Diagnostic Evaluation: Right Heart Cardiac
More informationFig.1 Normal appearance of RV in SAX:
Tutorial 7 - Assessment of the right heart Assessment of the Right heart The right heart assessment clinically and echocardiographically is not a very important part of mainstream cardiology. In the ICU,
More informationPrimary (idiopathic) pulmonary hypertension
Echocardiographic Features of Primary Pulmonary Hypertension Eduardo Bossone, MD, PhD, Thanh H. Duong-Wagner, MD, Giuseppe Paciocco, MD, Hakan Oral, MD, Mark Ricciardi, MD, David S. Bach, MD, Melvyn Rubenfire,
More informationPART II ECHOCARDIOGRAPHY LABORATORY OPERATIONS ADULT TRANSTHORACIC ECHOCARDIOGRAPHY TESTING
PART II ECHOCARDIOGRAPHY LABORATORY OPERATIONS ADULT TRANSTHORACIC ECHOCARDIOGRAPHY TESTING STANDARD - Primary Instrumentation 1.1 Cardiac Ultrasound Systems SECTION 1 Instrumentation Ultrasound instruments
More informationCardiac MRI in ACHD What We. ACHD Patients
Cardiac MRI in ACHD What We Have Learned to Apply to ACHD Patients Faris Al Mousily, MBChB, FAAC, FACC Consultant, Pediatric Cardiology, KFSH&RC/Jeddah Adjunct Faculty, Division of Pediatric Cardiology
More informationTricuspid and Pulmonary Valve Disease
Tricuspid and Pulmonary Valve Disease Lawrence Rudski MD FRCPC FACC FASE Professor of Medicine Director, Division of Cardiology Jewish General Hospital McGill University Right Sided Failure Edema Gut congestion
More informationPULMONARY HYPERTENSION
PULMONARY HYPERTENSION MARTIN T. MPE CARDIOLOGIST MEDICLINIC HEART HOSPITAL CASE REPORT A 35 year old female, general worker. Married with 2 children with the youngest aged 12 years. Presenting complaints
More informationPediatric Echocardiography Examination Content Outline
Pediatric Echocardiography Examination Content Outline (Outline Summary) # Domain Subdomain Percentage 1 Anatomy and Physiology Normal Anatomy and Physiology 10% 2 Abnormal Pathology and Pathophysiology
More informationFUNDAMENTALS OF HEMODYNAMICS, VASOACTIVE DRUGS AND IABP IN THE FAILING HEART
FUNDAMENTALS OF HEMODYNAMICS, VASOACTIVE DRUGS AND IABP IN THE FAILING HEART CINDY BITHER, MSN, ANP, ANP, AACC, CHFN CHIEF NP, ADV HF PROGRAM MEDSTAR WASHINGTON HOSPITAL CENTER CONFLICTS OF INTEREST NONE
More informationBogdan A. Popescu. University of Medicine and Pharmacy Bucharest, Romania. EAE Course, Bucharest, April 2010
Bogdan A. Popescu University of Medicine and Pharmacy Bucharest, Romania EAE Course, Bucharest, April 2010 This is how it started Mitral stenosis at a glance 2D echo narrow diastolic opening of MV leaflets
More informationPulmonary Hypertension. Murali Chakinala, M.D. Washington University School of Medicine
Pulmonary Hypertension Murali Chakinala, M.D. Washington University School of Medicine Pulmonary Circulation Alveolar Capillary relationship Pulmonary Circulation High flow, low resistance PVR ~1/15 of
More informationΚΑΡΔΙΟΛΟΓΟΣ EUROPEAN ACCREDITATION IN TRANSTHORACIC AND TRANSESOPHAGEAL ECHOCARDIOGRAPHY
1 ΚΑΡΔΙΟΛΟΓΟΣ EUROPEAN ACCREDITATION IN TRANSTHORACIC AND TRANSESOPHAGEAL ECHOCARDIOGRAPHY 2 Constrictive pericarditis (CP) is characterized by impaired ventricular filling due to a stiffened or noncompliant
More informationThe growing interest in pulmonary hypertension (PH) in
Eur Respir J 2010; 36: 986 990 DOI: 10.1183/09031936.00038410 CopyrightßERS 2010 EDITORIAL Pulmonary hypertension and pulmonary arterial hypertension: a clarification is needed N. Galiè, M. Palazzini and
More information